BioLife Foundation

Search This Blog

Flicker Gallery

1

Get link
Facebook
X
Pinterest
Email
Other Apps

Contact Us

Get link
Facebook
X
Pinterest
Email
Other Apps

*Name:

*Email:

*Message:

Submit

Get link
Facebook
X
Pinterest
Email
Other Apps

Tofacitinib clears pediatric alopecia areata in small study

Vitals Key clinical point: The JAK inhibitor tofacitinib resolved alopecia areata in 68% of pediatric patients. Major finding: Among the responders, the Severity of Alopecia Tool score improved by a mean 88% over 5 months. Data source: Case series of 13 pediatric patients with severe alopecia areata treated with tofacitinib at a single site. Disclosures: Ms. Liu and her collaborators reported no conflicts of interest. AT THE SPD ANNUAL MEETING MINNEAPOLIS – The first study to evaluate tofacitinib’s effectiveness at treating severe alopecia areata in the pediatric population found that the janus kinase inhibitor was effective for more than half of the patients, and well tolerated by all. Of a case series of 13 pediatric patients who had alopecia areata (AA) and were treated with tofacitinib, 9 (68%) experienced “clinically significant” regrowth of hair, with mean improvement in the Severity of Alopecia Tool (SALT) score of 88% for these responders. The nonrespondi...

Treating Common Hair Loss And Alopecia Areata by Using JAK Inhibitor Tofacitinib Topically

Having a full head of hair represents physical attractiveness and youthfulness to men and women, which is why hair loss can have significant negative impacts on the self-esteem and quality of life of those affected. A top medical expert and researcher since1993 Dr. Robert Setari has formulated a new topical treatment for hair loss, BioHair 7X® which includes Tofacitinib, Minoxidil, Melatonin and Bimatoprost. This unprecedented and unavailable anywhere else in the world hair loss treatment can only be obtained through your doctor or through BioLife Foundation Inc with a doctor’s prescription. Investigating hair loss and hair treatment since 1993, Dr. Robert Setari has always been decades ahead of the research. In 1993 Dr. Setari was the first physician to clinically study finasteride as a hair loss treatment. He began using oral finasteride for his patients… half a decade before Propecia became FDA approved and available to the general public. Now he has developed a Biohair ...

Introduction of BioLife

Powered by Blogger

Theme images by Airyelf

BioLife Foundation